11/15/2012

Tocilizumab, an interleukin-6 receptor inhibitor marketed as Actemra, significantly increased the height velocities of most patients with systemic juvenile idiopathic arthritis, according to a study presented at the American College of Rheumatology meeting. Higher insulinlike growth factor-1 levels and osteocalcin/C-telopeptide of type 1 collagen ratios linked to the use of the drug suggests the treatment can benefit growth hormone axis and bone metabolism, researchers said.

Related Summaries